LENSARLNSR
LNSR
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
86% more capital invested
Capital invested by funds: $17.5M [Q3] → $32.6M (+$15.1M) [Q4]
22% more funds holding
Funds holding: 36 [Q3] → 44 (+8) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
1.47% less ownership
Funds ownership: 32.83% [Q3] → 31.37% (-1.47%) [Q4]
79% less call options, than puts
Call options by funds: $109K | Put options by funds: $523K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
6%
upside
Avg. target
$15
6%
upside
High target
$15
6%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Lake Street Frank Takkinen 50% 1-year accuracy 11 / 22 met price target | 6%upside $15 | Hold Downgraded | 24 Mar 2025 |
Financial journalist opinion
Based on 8 articles about LNSR published over the past 30 days
Neutral
Business Wire
1 day ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
Positive
Zacks Investment Research
2 days ago
ALC Stock Rises Following the Merger Agreement With LENSAR
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Neutral
PRNewsWire
3 days ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR
NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon.
Neutral
Business Wire
3 days ago
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $3.
Neutral
Business Wire
3 days ago
LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LENSAR, Inc. (NASDAQ: LNSR) to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, is fair to LENSAR shareholders. Halper Sadeh encourages LENSAR shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.
Neutral
GlobeNewsWire
3 weeks ago
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
3 weeks ago
LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode.
Neutral
GlobeNewsWire
4 weeks ago
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on key operational initiatives.
Neutral
GlobeNewsWire
1 month ago
LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights.
Positive
Seeking Alpha
1 month ago
Medical Devices Firm Lensar Surges Ahead On Robotic Technology
LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth, with a one-year price target of $15.15, a 42.21% increase. Despite competition from larger firms, LENSAR's disruptive technology, expanding market share, and strong management team position it well for long-term growth.
Charts implemented using Lightweight Charts™